Janssen to acquire skin disease drug candidate bermekimab from XBiotech
Janssen Biotech acquisition of bermekimab: Janssen Biotech, a Janssen Pharmaceutical Company of Johnson & Johnson, has agreed to acquire all rights to bermekimab, an investigational ... Read More
Arena begins ADVISE clinical trial for etrasimod in atopic dermatitis
Arena Pharmaceuticals has dosed the first subject in the phase 2 ADVISE clinical trial, which is evaluating etrasimod for the treatment of moderate-to-severe atopic dermatitis ... Read More
Galderma launches phase 3 atopic dermatitis trial for nemolizumab
Galderma, a Nestle-owned Swiss pharma company, said that it has enrolled the first patients in a phase 3 clinical study evaluating nemolizumab for the treatment ... Read More
Teva launches generic version of Elidel Cream to expand eczema treatment options
Teva Pharmaceutical Industries has unveiled its generic version of Elidel (pimecrolimus) Cream, 1%, providing a more affordable treatment option for individuals battling mild to moderate ... Read More
LEO Pharma secures global rights to JW1601 in $402m deal with JW Pharmaceutical
LEO Pharma, a leading Danish pharmaceutical company, has acquired global exclusive rights to the atopic dermatitis drug JW1601 from JW Pharmaceutical (JWP), in a significant ... Read More
Novartis secures global rights to atopic dermatitis drug MOR106
In a strategic move to bolster its dermatology portfolio, Swiss pharmaceutical giant Novartis has entered into an agreement with MorphoSys and Galapagos to acquire exclusive ... Read More
Sanofi and Regeneron’s Dupixent receives FDA approval for atopic dermatitis treatment
Sanofi and Regeneron Pharmaceuticals have announced a significant advancement in dermatological care with the U.S. Food and Drug Administration (FDA) approving Dupixent (dupilumab) for the ... Read More
Sanofi and Regeneron’s Dupixent shows promising results in Phase 3 eczema trial
Sanofi and Regeneron Pharmaceuticals have achieved a significant milestone with their jointly developed eczema drug, Dupixent (dupilumab), meeting the primary endpoints in a year-long Phase ... Read More